About this content About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical ...

关于Avanos Medical公司参会信息 - 公司临时首席执行官Michael Greiner将参加于2024年11月12日周二太平洋时间约下午2:45的瑞银2024医疗保健会议的炉边谈话[1] - 会议报告的网络直播将在Avanos Medical网站的投资者板块提供并将在该网站存档[1] 关于Avanos Medical公司概况 - 公司是一家医疗技术公司专注于提供临床卓越的医疗设备解决方案以帮助患者回归正常生活总部位于佐治亚州阿尔法利塔致力于解决当今一些最重要的医疗保健需求包括为患者从医院到家庭提供重要的营养生命线以及在帮助患者从手术到康复过程中减少阿片类药物的使用[2] - 公司在全球开发制造和营销其知名品牌并在其产品组合的多个类别中占据领先市场地位[2] - 可通过访问Avanos.com以及在X (@AvanosMedical)、领英和脸书上关注公司获取更多信息[2] 关于新闻来源相关 - 新闻来源为Avanos Medical[3]

THOUSAND OAKS, Calif., Nov. 8, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m. PT on Wednesday, Nov. 13, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in A ...

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 12:30 PM EST and participate in one-on-one investor meetings. The webcast of the ...

MARLBOROUGH, Mass., Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024.Nick Spadea-Anello, president, Electrophysiology, and Jon Monson, senior vice president, Investor Relations, will participate in a 35-minute question-and-answer session with the host analyst at approximately 7:15 a.m. PT / 10:15 a.m. ET. A live webcast and replay of the session will be accessible at htts://investors.bostonscien ...

PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, ...

BEIJING, Oct. 31, 2024 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S.-listed EV charging service company in China, today announced that Mr. Steven Sim, Chief Financial Officer of NaaS, will be featured on UBS's Charging Industry Call Series on November 4, 2024.Event: UBS Charging Industry Call Series – "Charged Up: Inflection of Earnings"Moderator: Ms. Wei Shen, Head of China Auto Research, UBSFeatured Guest: Mr. Steven Sim, Chief Financial Officer of NaaSDate ...

CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the UBS Global Healthcare Conference, taking place November 11-14, ...

文章核心观点 - 公司第三季度净利润同比大幅增长,主要得益于财富管理、资产管理和投资银行业务的强劲表现,以及营业费用的下降 [1] - 公司正在执行整合计划,去风险化资产负债表,并实现成本削减目标 [9][11] - 公司正在加快整合瑞信的客户账户和数据迁移,预计到2026年底实现130亿美元的总成本节约 [10][11] 公司财务表现 - 公司总收入同比增长5%至123亿美元 [2] - 营业费用同比下降12%至103亿美元 [2] - 信贷损失费用同比增加27.4%至1.21亿美元 [2] - 资产总额环比增长4%至1.62万亿美元 [8] - 普通股一级资本收益率为7.6%,去年同期为负3.7% [8] - 风险加权资产同比下降4.9%至5194亿美元 [8] - 普通股一级资本同比下降3.5%至742亿美元 [8] - 管理资产规模同比增长15%至6.2万亿美元 [8] 业务部门表现 - 财富管理业务营业利润同比增长17.2%至11亿美元,主要受益于经常性净费用和交易收入的增加 [4] - 资产管理业务营业利润同比大幅增长,主要得益于出售巴西房地产基金管理业务和瑞信保险挂钩策略公司股权的净收益 [5] - 个人及企业银行业务营业利润同比下降11.6%至8.46亿美元,主要由于收入下降 [5] - 投资银行业务营业利润由去年同期的亏损转为盈利4.05亿美元,主要得益于收入增加和费用下降 [6] - 非核心及遗留业务亏损同比收窄 [6] - 集团项目营业利润由去年同期亏损转为盈利 [7]

财务数据和关键指标变化 - 第三季度净利润为14亿，税前利润为24亿，显示出强劲的财务表现 [4][16] - 总收入同比增长9%，达到117亿，运营费用下降4%，至92亿 [16][18] - CET1资本比率为14.3%，略高于指导水平 [22][24] 各条业务线数据和关键指标变化 - 全球财富管理部门税前利润为13亿，同比增长30% [29] - 个人与企业银行部门税前利润为6.59亿，下降7% [36] - 资产管理部门税前利润增长46%，达到2.37亿 [39] 各个市场数据和关键指标变化 - 美洲和亚太地区的收入增长显著，尤其是亚太地区的税前利润同比增长超过100% [30] - 投资银行部门的收入增长29%，达到25亿 [41] 公司战略和发展方向和行业竞争 - 公司致力于整合并提升客户体验，计划在2025年完成瑞士的客户账户迁移 [7][9] - 公司将继续投资于云基础设施和人工智能，以增强长期增长潜力 [10][11] 管理层对经营环境和未来前景的评论 - 管理层对未来的市场环境持谨慎乐观态度，认为全球宏观经济和地缘政治因素可能影响投资者行为 [13] - 公司预计2025年的资本回报将超过收购前水平 [9] 其他重要信息 - 公司在非核心和遗留业务方面继续简化操作，预计到2026年将减少风险加权资产 [8][45] - 公司在第三季度实现了7.5亿的年度化成本节省，朝着130亿的目标迈进 [20] 问答环节所有提问和回答 问题: 关于2025年的回购计划 - 管理层重申2025年将进行股票回购，具体金额将在2024年第四季度的结果中公布 [48][49] 问题: 关于美国财富管理的收益 - 管理层表示，低利率将刺激贷款机会，尽管存款流出仍然存在 [52] 问题: 关于2025年的盈利预期 - 管理层指出，尽管当前的回报率为9.2%，但不应直接推断2025年的表现 [54][56] 问题: 关于资产管理的市场动态 - 管理层强调，资产管理部门的表现与市场动态和客户需求密切相关 [39][41] 问题: 关于投资银行的表现 - 管理层表示，投资银行的强劲表现得益于团队的整合和市场的支持 [41][82]